For example, in thetreatment of prostate cancer, the goal is to reduce androgen synthesis,so a highly specific and potent inhibitor of CYP17A1 would be ideal.On the other hand, in the treatment of congenital adrenal hyperplasia,a less potent inhibitor that does not completely shut down steroidogenesismay be preferred to avoid significant hormonal imbalances. This evidence concerns the gene CYP17A1 and prostate cancer.